Concepedia

Author

Stefania Oliva

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoORCID

Also Known As

S Oliva, S. Oliva, S., Oliva, Stefania Oliva

64

Publications

4.7K

Citations

26

H-Index

38

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoSapienza University of RomeUniversity of TurinFondazione IRCCS Istituto Nazionale dei TumoriIstituti di Ricovero e Cura a Carattere Scientifico
SO

About

Stefania Oliva is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

13

1.1K

2

Health Sciences

7

7

538

3

Blood Transplantation

2

2

348

4

Public Health

1

1

26

5

Cellular Therapies

1

1

36

Stefania Oliva

×

27

Publications

4K

Citations

23

H-Index

YearCitations

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo, Hervé Avet‐Loiseau, Stefania Oliva,

Journal of Clinical Oncology

2015

2.1K

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç,

The Lancet Haematology

2020

377

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci,

The Lancet Oncology

2015

312

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Ajai Chari, Mehmet Samur, Joaquín Martínez‐López,

Blood

2020

181

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Sara Bringhen, Maria Teresa Petrucci, Alessandra Larocca,

Blood

2014

153

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

Simone Ferrero, Marco Ladetto, Daniela Drandi,

Leukemia

2014

83

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Francesca Gay, Valeria Magarotto, Claudia Crippa,

Blood

2013

81

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini,

Journal of Clinical Oncology

2022

79

Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

Mattia D’Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu,

Clinical Cancer Research

2020

62

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Mariateresa Fulciniti, Joaquín Martínez‐López, William Senapedis,

Blood

2017

46

Page 1